Skip to content
Free for 3 months · no credit card

DE NOVO DRUG DESIGN FOR AGE-RELATED DISEASE

Design new
drug candidates for
age-related disease.

Pick an ageing protein, a tissue, and the kind of age-related damage. In a few minutes you get up to 12 brand-new candidate molecules — each with a proposed synthesis route, the age-related disease it addresses, and the endpoint it would be filed against. 3 design runs a month, free.

Work email verification. Research use only.

THE SPACE YOU DESIGN INFIG. 001
Biology informs the question.
Chemistry makes it testable.

Everything you can design against,
in one workspace.

21runnable targets
14tissue contexts
12aging hallmarks
55age-related diseases

01 / A DIFFERENT STARTING POINT

Beyond a single target.
A wider view of discovery.

A target is only part of the story. Explore it alongside tissue context and aging biology—then see the chemistry, the trade-offs, and the evidence in one place.

01

Biology in context

Lifespan and rejuvenation research, clearly distinguished. Tissue and hallmark context travels with the design.

02

Routes, not just structures

Every candidate is built from chemical building blocks and reactions. Review a proposed synthesis route alongside each delivered candidate.

03

Clarity over confidence

See where a prediction leaves familiar chemistry. Inspect uncertainty instead of mistaking a high score for proof.

THE LIVING ATLAS / EXPLORE, DON'T JUST SCROLL

Choose a tissue.
Follow an aging process.

Two lenses. One research question. Explore the body and the hallmarks of aging, then bring your chosen context into molecular design.

SELECT A NODE TO EXPLORE
Realistic anatomical illustration of the human body with selectable tissue contexts
Schematic tissue map · not an anatomical model

WHERE YOU ARE LOOKING

Liver

Metabolism & clearance

Review predicted liver injury and drug interactions. Tissue intent does not establish liver selectivity.

TISSUELiver
AGING PROCESSEpigenetics
Explore target chemistry
AN EXPERIMENTAL QUESTION TO ASK

Does a molecular change reflect better cell function, rather than only a change in a clock readout?

Your selections are research lenses, not evidence of a causal tissue–hallmark interaction. No prediction or design job is run here. Hallmarks follow López-Otín et al., Cell (2023).

NOW, WHERE IT LANDS

Your tissue and your aging process,
carried all the way to a disease and its endpoint.

Pick a tissue. You get a molecule, with its synthesis route, that addresses a mechanism implicated in a named disease, judged on a real regulatory endpoint.

YOUR TISSUE
YOUR AGING PROCESSEpigeneticsCarried from the atlas above
  1. YOUR MOLECULE ADDRESSES A MECHANISM IMPLICATED INMASH with F2–F3 fibrosis
  2. AND IS JUDGED ON A REAL REGULATORY ENDPOINTLiver histology at 12 months accelerated-approval surrogate
  3. YOU RECEIVEA molecule with its synthesis routeDesigned for Liver and Epigenetics. Building blocks and reactions, ready for the bench.

315 of 315 target and tissue pairings come back with a disease and an endpoint, across 55 age-related diseases and 11 body systems.

Could it be approved? See who already did it
See how the search is structured

THE MAP OF YOUR FIELD

55 age-related diseases.
Your target is in here.

Every disease is grouped the way a clinician reads it. Choose a tissue and watch it light up across the body systems it touches.

  • 55age-related diseases
  • 11body systems
  • 315 of 315target and tissue pairings answered

Liver shows up in 3 diseases across 1 body system.

METABOLIC & ENDOCRINE · 3 DISEASES

Metabolic & Endocrine

  • Type 2 diabetesLiverThe body stops responding to insulin and the pancreas cannot keep up.
  • Metabolic syndromeLiverBelly fat, high blood pressure, high sugar and bad cholesterol together.
  • MASH (fatty liver with inflammation and scarring)LiverFat and scarring build up in the liver and slowly damage it.

Pick any target and any tissue: all 315 pairings come back with a disease and an endpoint.

Create your free account

THIS PATH IS WALKED

The protein is proven ground.
The molecule is a new design.

You are not betting on a new target. You are betting on new chemistry against a protein that already has an approved medicine, made by another company and on the record with a date. We start a fresh molecule from there.

  • 9approved medicines from other companies, on the same proteins
  • 16 of 21targets have already reached human trials
  • All 21targets accounted for
PROVEN GROUND · ON THE RECORDVenetoclax (Venclexta)

Another company's medicine. FDA-approved Apr 2016 against BCL-2.

YOUR CANDIDATE · A NEW DESIGNNew chemistry on BCL-2

A molecule designed from scratch against the same protein, with its own synthesis route and its own evidence.

BUT HOW DO YOU KNOW IT BINDS?

We don't predict harder.
We hand you a molecule the comparison can reach.

A score on brand-new chemistry is a confident number from outside its own evidence. So every candidate can arrive with a sibling on the same route, one building block apart, that sits nearer to known binders.

  1. SCAFFOLDSame
  2. REACTION 1Same
  3. REACTION 2Same
  4. ONE BUILDING BLOCKOriginal
SIMILARITY TO THE TARGET'S REAL BINDERS · MEDIAN, 21 TARGETS0.19

126 of 176 delivered molecules carry a sibling, and because it shares the route it is makeable, not hypothetical.

  • 21 targets
  • 14 tissues
  • 315 target-and-tissue pairings, all answering
  • 55 diseases

Every number we show says where it stops. When a similarity reading sits outside the range it was measured on, we tell you, instead of printing a confident score.

Say exactly what the molecule does, and nothing more.

Every candidate addresses a mechanism implicated in a named disease, with the endpoint it would be judged on. That precision is what keeps the path to approval credible.

Create your free account

THE SEARCH LAYER / QUANTUM-INSPIRED, CLASSICALLY COMPUTED

Inside the search.
Explore every operator.

9 registered8 integrated · 1 prototypeMaster flag off by default

A shared tissue × hallmark representation, with diagnostics kept distinct from measured biology. Select an entry to see its inputs, operation, output and boundary.

REGISTERED OPERATOR SETV1.1

Conceptual representation · no job, score or API request runs in this preview.

OPERATOR DETAILIntegrated · master flag required

target-state distance

QASE

Compares a 22-component representation with a target-state prior.

INPUT

Ten tissue ECR components and each molecule’s hallmark-localization profile.

OPERATION

Builds a 22-component representation and compares it with the target-state prior.

OUTPUT

A target-state distance for each candidate.

STAGE

Post-selection description

STATUS

Integrated · master flag required

ENGINE FLAG

GEROQUBIT_QX=1

BoundaryThe target weights are priors, not measured efficacy or a predicted treatment effect.

The QX master flag is off unless explicitly set; this explorer is not a set of controls that enables engine flags. QRC decoder reordering requires its own opt-in. No quantum hardware advantage or efficacy result is implied.

02 / FOLLOW YOUR QUESTION

Big questions.
Molecular starting points.

Pick a target to explore a research context. This is a guided product preview, not a generated result or a treatment recommendation.

Explore all 21 targets
RESEARCH CONTEXT01 / 04
SIRT6

Explore the chemistry of cellular maintenance.

Investigate a chromatin-associated target at the intersection of lifespan and rejuvenation research.

Biological context
Chromatin · DNA repair

Activation is a design objective, not a measured property of a generated molecule.

Your research note: Epigenetic alterations. Hallmark selection is context, not an independent generation control.

Use this research context

11 lifespan targets and 10 additional rejuvenation targets. SIRT6 bridges both research areas; their scores are not interchangeable.

03 / FROM QUESTION TO CANDIDATE

Not another score.
A clearer next step.

Inspect a worked candidate
CANDIDATE WORKSPACE / OUTPUT PREVIEWGQ
Example molecular structure from a previously generated route
StructureDescriptorsExport

Example structure · not experimentally validated

A structure you can inspect.

Review molecular structures, physicochemical properties and similarity to reference compounds. Export candidates for your own analysis.

  • 2D & 3D molecular views
  • QED, synthetic accessibility and descriptors
  • CSV & SDF exports
Try it with your research question
01 Choose a target, tissue & aging process02 Generate & inspect03 Export & test independently

04 / SCIENCE WITHOUT THE FINE-PRINT TRAP

Know the promise.
See the limits.

Novel chemistry is precisely where predictions become less reliable. We show that boundary—not just the most flattering benchmark.

Read the full evidence
RETROSPECTIVE BINDER RECOVERY
0.681ROC-AUC
Novel-chemotype slice
0.000.50 · chance1.00

Performance falls on unfamiliar chemistry. Treat predictions as hypotheses for testing, not experimental measurements.

Longevity efficacy is not established. External lifespan tests did not demonstrate ranking ability: mouse ITP AUC 0.645, 95% CI [0.447, 0.826]; worm MMC correlation −0.023 (p = 0.796). These limitations remain visible in the full benchmark.

YOUR NEXT QUESTION STARTS HERE

We launch next month.
Start now, free.

Not a waitlist — the platform runs today. Create an account now and your free runs carry straight through launch.

Create your free account

Work or institutional email. No credit card.

Freefor 3 months
  • 3 design runs every month
  • Up to 12 candidates per run
  • All 21 runnable targets
  • Structures, predicted safety & proposed routes
  • CSV, SDF & protocol exports

Need longer or more capacity? Talk to us about an extension

Candidate yield depends on chemistry and safety filters. Personal email addresses require review. Accounts created before launch keep their free runs; existing results stay available. View access details.

A FEW THINGS WORTH KNOWING

Before you
begin.

More questions, answered
01What is included in free access?

3 months of access, 3 design runs each month, and up to 12 candidates per run. Explore all 21 runnable targets, inspect results and export your candidates. Safety and chemistry filters may return fewer candidates, including none.

02Do I need to join a research programme?

No. GeroQubit is a product you can use directly. Register with your work or institutional email and verify it to activate self-serve access. Personal email addresses go through manual review. No credit card is required.

03What happens at launch?

Nothing you have is taken away. Accounts created before launch keep their free runs, and existing results remain available. Paid tiers arrive at launch; nothing converts to a paid subscription automatically, and we will not bill an account that has not asked to be billed.

04Are the molecules experimentally validated?

No. These are computationally designed research candidates. Predicted binding, safety and aging-related signals require independent synthesis and experimental testing. GeroQubit does not provide medical advice or compounds for human use.